#USA #Veeva Systems #Drug Development #biotechnology #Pleasanton

Accelerating Drug Development: Veeva Basics Empowers Emerging Biotechs

In the dynamic world of biotechnology, where time can mean the difference between life and death, Veeva Systems is stepping up to help emerging companies streamline their processes. Recently, Veeva announced that more than 175 emerging biotech companies have opted for its innovative solution, Veeva Basics, to create a robust technological foundation necessary for efficient drug development.

Enhancing Efficiency with Pre-Configured Solutions

The beauty of Veeva Basics lies in its pre-configured applications, which can be rolled out in just weeks rather than the usual months associated with traditional systems. This efficiency allows biotechnology startups to avoid the lengthy and costly setup processes often required for software implementations.

As Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, aptly put it, “As a growing company with under 40 employees, we’re focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers.” He noted that by partnering with Veeva, his firm has been able to transition from outdated paper processes to a streamlined approach that enhances productivity without the need for an extensive IT team.

Flexibility and Scalability for Growth

One of the standout features of Veeva Basics is its scalability, catering to companies as they move from startup to commercialization. These applications provide a cohesive infrastructure that supports growth across multiple dimensions: clinical, regulatory, quality, medical, and commercial operations, thereby assisting firms in navigating the complexities of drug development swiftly and effectively.

Long gone are the days when companies relied heavily on outsourced regulatory publishing strategies. Veeva Basics facilitates insourced solutions, allowing firms to manage submission publishing in-house, drastically improving quality control and reducing timelines. Darryl Clarke, Global Head of Regulatory Operations at Structure Therapeutics, pointed out that insourcing has led to “sharper quality control and significantly faster regulatory timelines.”

A Community of Innovators

The introduction of Veeva Basics coincides with a growing need for innovative solutions in the biotech space. As noted by Jim Thai, Vice President of Veeva Basics, “Biotechs are responsible for so much of the innovation shaping the industry, and they need technology that reflects the pace that they operate in.” Veeva’s mission resonates with this sentiment, aiming to equip these pioneers with tools that enhance their operational capabilities.

Conclusion: A Bright Future with Veeva

The integration of Veeva Basics into 175 emerging biotechs illustrates a significant shift in how these companies can approach drug development. With a solid technology foundation that promises growth, efficiency, and compliance, Veeva Basics stands out as a vital asset in the biotechnology landscape. Interested firms can learn more about Veeva Basics on their official website, veevabasics.com, and can also register for the upcoming Veeva RD and Quality Summit taking place on October 20-21 in Boston, an exclusive event for life sciences professionals.

In the highly competitive world of biotech, adopting such forward-thinking technology could be the key to not only surviving but thriving in the rush to deliver life-saving therapies to patients who need them most.